Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment

Inclusion Criteria:

1. Documented malignant epithelial mesothelioma, cancer of the pancreas or ovaries or non-small-cell lung cancer (NSCLC) and who have failed (or are not candidates for) standard therapy
2. ECOG Performance Status of 0 to 1, or Karnofsky Performance Status (KPS) of 80-100%
3. Adequate organ function as defined by study-specified laboratory tests
4. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug
5. Signed informed consent form
6. Willing and able to comply with study procedures

Exclusion Criteria:

1. History of infection with Listeria, prior vaccination with a listeria-based vaccine, or a positive fecal culture of Listeria at screening
2. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions
3. Allergy to penicillin or yeast or other component of the study drug product (e.g., glycerol)
4. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0
5. Artificial (prosthetic) joint or other artificial implant or devices that cannot be easily removed
6. Certain types of blood transfusions within 14 days prior to receiving study drug or a condition requiring regular blood transfusions more than twice per month
7. Taking the following medications:

   * Anti-coagulation medications
   * Systemically active steroids for more than 2 days within 28 days prior to receiving study drug
   * More than 325 mg per day of aspirin
   * More than 2 g per day of acetaminophen
   * Systemic antibiotics within 14 days prior to receiving study drug
   * Another investigational product within 28 days prior to receiving study drug
8. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
9. Infection with HIV, hepatitis B or C, or HTLV-1 (human t-lymphotropic virus type 1) at screening
10. Pregnant or lactating, or close contact with pregnant women or newborn babies
11. Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures